TMO as reported
Thermo Fisher Scientific reported $46.3B of revenue over the trailing twelve months, +7.2% on the year before. 11 reported series are charted on this page, each one as filed.
$46.3B
Revenue, trailing twelve months · to Q2 2026 · +7.2% against the twelve months before
- Net Income
- $6.97B
Net Income · +5.8% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $7.32B
Free Cash Flow · +19% year on year · trailing twelve months to Q2 2026
- Op Margin
- 18%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $46.3B | +7.2% | Q2 2026 |
| Net Income | $6.97B | +5.8% | Q2 2026 |
| EPS | $18.59 | +7.5% | Q2 2026 |
| Gross Margin | 44% | n/a | Q4 2019 · 26 quarters behind |
| Op Margin | 18% | n/a | Q2 2026 |
| Net Margin | 15% | n/a | Q2 2026 |
| ROE | 13% | n/a | Q2 2026 |
| ROA | 6.2% | n/a | Q2 2026 |
| ROIC | 7.1% | n/a | Q2 2026 |
| Free Cash Flow | $7.32B | +19% | Q2 2026 |
| P/E | 34.1 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Thermo Fisher Scientific (TMO) - Revenue & ProfitRevenue & ProfitThermo Fisher Scientific (TMO)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Diagnostics & Research
Ranks #9 of 29 by Smart Score